ROIV - Roivant Sciences Ltd.

QQQ $ 474.63 $ 1.20 (0.25 %)

DIA $ 414.76 $ 2.13 (0.52 %)

SPY $ 561.41 $ 1.14 (0.2 %)

TLT $ 100.48 $ 0.00 (0 %)

GLD $ 238.66 $ 1.07 (0.45 %)

Previous Close

$ 12.12

Open

$ 12.21

Bid

$ 11.96 x 600

Ask

$ 11.97 x 500

Day's Range

$ 11.97 - $ 12.27

52 Week Range

$ 8.25 - $ 13.24

Volume

4,060,020

Average Volume

Market Cap

8.96B

Beta (5Y Monthly)

$ 0.86

PE Ratio (TTM)

$ 1.89

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-09-2024	06-30-2024	10-Q
2	05-30-2024	03-31-2024	10-K
3	02-13-2024	12-31-2023	10-Q
4	11-13-2023	09-30-2023	10-Q
5	08-14-2023	06-30-2023	10-Q
6	06-28-2023	03-31-2023	10-K
7	02-13-2023	12-31-2022	10-Q
8	11-14-2022	09-30-2022	10-Q
9	08-15-2022	06-30-2022	10-Q
10	06-28-2022	03-31-2022	10-K
11	02-14-2022	12-31-2021	10-Q
12	11-15-2021	09-30-2021	10-Q
13	09-21-2021	06-30-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

4 Analysts Assess Roivant Sciences: What Y...
09/11/2024 14:00:41

B of A Securities Maintains Neutral on Roi...
09/11/2024 13:13:25

B of A Securities analyst Chi Fong maintains Roivant Sciences (NASDAQ:ROIV) with a Neutral and raises the price target from ...

HC Wainwright & Co. Reiterates Buy on Roiv...
09/11/2024 10:32:30

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price ta...

roivant-sciences-unveils-new-vant-subsidiary-for-in-licensed-pulmonary-hypertension-drug-from-bayer

Roivant Sciences Unveils New 'Vant' Subsid...
09/10/2024 18:21:15

Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $...

Pulmovant, A Roivant Company, Announced Th...
09/10/2024 10:33:30

whats-going-in-with-vivek-ramaswamy-founded-roivant-sciences-stock-on-monday

What's Going In With Vivek Ramaswamy-Found...
09/09/2024 16:54:13

Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rat...

Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 13:03:05

Cantor Fitzgerald analyst Louise Chen reiterates Roivant Sciences (NASDAQ:ROIV) with a Overweight.

Roivant Says Immunovant Reported Results F...
09/09/2024 11:06:51

mmunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD tr...

HC Wainwright & Co. Reiterates Buy on Roiv...
08/19/2024 10:43:13

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price ta...

Roivant Sciences Q1 2025 Adj. EPS $(0.17) ...
08/08/2024 11:08:03

Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0....

Piper Sandler Maintains Overweight on Roiv...
07/10/2024 14:09:59

Piper Sandler analyst Allison Bratzel maintains Roivant Sciences (NASDAQ:ROIV) with a Overweight and raises the price target...

Evaluating Roivant Sciences: Insights From...
06/18/2024 15:00:13

Cantor Fitzgerald Reiterates Overweight on...
06/18/2024 14:07:26

Cantor Fitzgerald analyst Louise Chen reiterates Roivant Sciences (NASDAQ:ROIV) with a Overweight.

The Analyst Verdict: Roivant Sciences In T...
05/31/2024 14:00:16

HC Wainwright & Co. Reiterates Buy on Roiv...
05/31/2024 10:38:57

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price ta...

Roivant Sciences Q4 2024 GAAP EPS $(0.19) ...
05/30/2024 11:02:13

Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0....

vivek-ramaswamy-breathes-new-life-into-beaten-down-buzzfeed-stock-whats-going-on

Vivek Ramaswamy Breathes New Life Into Bea...
05/22/2024 12:04:01

BuzzFeed shares surged after Vivek Ramaswamy acquired a 7.7% stake for $3.2 million.

Roivant And Kinevant Sciences Complete Enr...
04/25/2024 12:08:24

Critical Insights From Roivant Sciences An...
04/22/2024 15:01:12

HC Wainwright & Co. Reiterates Buy on Roiv...
04/22/2024 10:34:04

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price ta...